文献速递血栓与止血

延长半衰期凝血因子增强基因治疗疗效

Increased gene therapy efficacy through the use of extended half-life clotting factors.
PubMed 文献 · Blood Adv · 2026-01-01

该研究在野生型和血友病B小鼠中比较了编码FIX-R338L-ALB(QMP)融合蛋白的AAV载体与对照载体。结果显示融合载体使FIX抗原水平和活性分别持续提高4倍和3倍,出血表型持续纠正,且未增加免疫原性、肝毒性或血栓风险,多数小鼠实现免疫耐受。

要点

  • AAV-FIX-R338L-ALB(QMP)使FIX抗原和活性分别持续提高4倍和3倍
  • 融合载体未增加抗FIX抗体、转氨酶升高或肝脏免疫浸润
  • 多数血友病B小鼠经治疗实现由调节性T细胞介导的免疫耐受

核心结论

  • 编码延长半衰期FIX的FIX-R338L-ALB(QMP)融合构建体是血友病B有前景的下一代基因治疗策略。

研究设计与样本

  • 研究将编码FIX-R338L-ALB(QMP)的AAV载体给予野生型和血友病B小鼠,并与编码FIX-R338L的对照AAV载体比较。

主要发现

  • AAV-FIX-R338L-ALB(QMP)较对照AAV-FIX-R338L使FIX抗原水平和活性分别持续提高4倍和3倍。
  • FIX抗原和活性提高与出血表型持续纠正一致。
  • 治疗后未检测到抗FIX抗体、丙氨酸转氨酶升高或肝脏免疫浸润,免疫原性或肝毒性未增加。
  • 多数接受AAV-FIX-R338L-ALB(QMP)治疗的血友病B小鼠在FIX蛋白加佐剂主动免疫后仍实现免疫耐受,且由调节性T细胞介导。
  • D-二聚体水平稳定,未观察到血栓风险增加。

临床怎么用

  • 该融合构建体可能通过提高FIX抗原水平和活性来增强血友病B基因治疗疗效。
  • 治疗未增加免疫原性、肝毒性或血栓风险,并可能促进免疫耐受。

局限性

  • 研究结果基于野生型和血友病B小鼠,尚未在人体中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of more effective gene therapy strategies for hemophilia B remains essential because results of multiple clinical trials show significant interpatient variability in clinical outcomes, with a fraction of patients (up to 13%) even returning to prophylaxis. Another major challenge in current adeno-associated viral (AAV)-based gene therapy for hemophilia B pertains to dose-dependent vector-related immune responses, requiring immune suppression. We investigated whether combining gene therapy with transgenes encoding extended half-life (EHL) coagulation factors could enhance therapeutic efficacy. AAV vectors encoding a hyperactive factor IX variant R338L (ie, FIX-Padua), genetically fused to a mutant human albumin (FIX-R338L-ALB[QMP]), were administered to both wild-type and hemophilia B mice. These chimeric transgenes were codon-optimized and driven by a hepatocyte-specific promoter. The AAV-FIX-R338L-ALB(QMP) vector demonstrated significantly improved efficacy compared with the control AAV-FIX-R338L vector, resulting in a sustained fourfold and threefold increase in FIX antigen levels and activity, respectively. These increases were consistent with durable correction of the bleeding phenotype. Importantly, immunogenicity or liver toxicity was not increased because no anti-FIX antibodies, alanine transaminase elevations, or liver immune infiltrations were detected after treatment. Furthermore, immune tolerance was achieved in most hemophilia B mice treated with AAV-FIX-R338L-ALB(QMP), even after active immunization with FIX protein and adjuvant, which was found to be mediated by regulatory T cells. In addition, no increase in thrombogenic risk was observed, indicated by stable D-dimer levels. These findings support the potential of FIX-R338L-ALB(QMP) fusion constructs encoding EHL FIX as a promising next-generation gene therapy for hemophilia B.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. De Wolf D, Nguyen PA, Nair N, et al. Increased gene therapy efficacy through the use of extended half-life clotting factors. Blood Adv. 2026. PMID: 42392182. doi:10.1182/bloodadvances.2025018891

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。